In humans, the skin is a target tissue for androgen action; hair growth and sebum secretion are under active androgen control. An increased production or metabolism of testosterone, the main active androgen, shows up clinically in dermatological symptoms such as hirsutism, hyperseborrheic acne and alopecia. Polycystic ovary syndrome (PCOS) is the most frequent androgen disorder of ovarian function. PCOS patients have amenorrhea or severe oligomenorrhea, increased testosterone levels and most often enlarged polycystic ovaries on ultrasound examination. In addition, many PCOS patients have a tendency to accumulate abdominal fat and/or to develop obesity. Some also display a particular metabolic pattern including an atherogenic lipid profile, glucose intolerance and an increased fasting insulin level, which is known to be closely linked with an insulin resistant state. Several studies have now reported that PCOS patients show increased incidence of type 2 diabetes and cardiovascular disease. In addition to being a target for androgens the skin has abundant insulin receptors on the keratinocyte surface membrane and acanthosis nigricans is a common symptom of severe insulin resistance among patients with insulin receptor disorders. However, acanthosis nigricans could also be present in PCOS women given evidence of the intensity of their insulin resistance. This presentation will review the mutual relationship between hyperandrogenia and insulin resistance, with particular attention paid to: (1) insulin secretion and insulin sensitivity in PCOS; (2) the complexity of the molecular mechanisms involved in insulin resistance; (3) the paradoxical relationship between insulin resistance and hyperandrogenia; (4) the current genetic studies; and (5) new avenues for long-term treatment of PCOS women.

Keywords:
Androgens, Insulin resistance, Hyperandrogenia, Acanthosis nigricans, Hirsutism, Alopecia
1.
Androgen secreting ovarian neoplasms; in Azziz R, Nestler and Devailly D (eds): Androgen Excess Disorders in Women. Philadelphia/New York, Lippincott-Raven, 1997, pp 555–568.
2.
Rosner W: The functions of corticosteroid-binding globulin and sex hormone-binding globulin: Recent advances. Endocr Rev 1990;11:80–91.
3.
Hammond GL: Potential functions of plasma steroid-binding proteins. Trends Endocrinol Metab 1995;6:298–304.
4.
Pugeat M, Crave JC, Elmidani M, Nicolas MH, Garoscio-Cholet M, Lejeune H, Déchaud H, Tourniaire J: Pathophysiology of sex hormone-binding globulin (SHBG): Relation to insulin. J Steroid Biochem 1991;40:841–849.
5.
Serafini P, Ablan F, Lobo RA: 5alpha-Reductase in the genital skin of hirsute women. J Clin Endocrinol Metab 1985;60:349–355.
6.
Vottero A, Stratakis CA, Ghizzoni L, Longui CA, Karl M, Chrousos GP: Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: Skewing of X-chromosome inactivation. J Clin Endocrinol Metab 1999;84:1091–1095.
7.
Labrie F, Bélanger A, Simard J, Liuu-The V, Labrie C: DHEA and peripheral androgen and estrogen formation: Intracrinology; in Bellino FL, Daynes RA, Hornsby PJ, Lavrin DH, Nestler JE (eds): Dehydroepiandrosterone (DHEA) in aging. Ann NY Acad Sci 1995;74:16–28.
8.
Jeffcoate W, Kong MF: Diabète des femmes à barbe: a classic paper reread. Lancet 2000;356:1183–1185.
9.
Franks S: Medical Progress: Polycystic ovary syndrome. N Engl J Med 1995;28:853–861.
10.
Barbieri RL: Hyperandrogenism, insulin resistance and acanthosis nigricans: 10 years of progress. J Reprod Med 1994;39:327–336.
11.
Poretsky L: Insulin resistance and hyperandrogenism: Update 1994. Endocr Rev 1994;2:125–129.
12.
Pugeat M, Ducluzeau PH: Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999;58(suppl 1):41–46.
13.
Dunaif A: Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Rev 1997;6:774–800.
14.
Holte J, Bergh T, Berne C, Berglund L, Lithell H: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994;78:1052–1058.
15.
O’Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Rosenfield RL, Jaspan JB, Polonsky KS: Defect in beta cell function in functionnal ovarian hyperandrogenism. J Clin Endocrinol Meatb 1993;76:1241–1247.
16.
Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS: Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15:1266–1274.
17.
Ciaraldi TP, El-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC: Cellular mechanisms of insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 1992;75:577–583.
18.
Dunaif A, Xia J, Book C, Schenker E, Tang Z: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801–810.
19.
Zhang LH, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450c17 increases 17,20 lyase activity: Implications of adrenarche and the polycystic ovary syndrome. Proc Nat Acad Sci USA 1995;92:10619–10623.
20.
Ehrman DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;13:322–353.
21.
Aguirre V, White MF: Dysregulation of IRS-proteins causes insulin resistance and diabetes. Curr Opin Endocrinol Diabetes 2000;7:1–7.
22.
Czech MP, Corvera S: Signaling mechanisms that regulate glucose transport. J Biol Chem 2000;274:1865–1868.
23.
Pessin JE, Saltiel AR: Signalling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest 2000;106:165–169.
24.
Rosenbaum D, Haber RS, Dunaif A: Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993;264:E197–E202.
25.
Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A: Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Nat Acad Sci 1998;95:14956–14960.
26.
Franks S, Gharani N, Waterworth DM, Batty S, White D, Williamson R, McCarthy M: The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641–2648.
27.
Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF, Spielman RS, Dunaif A: Thirthy-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Nat Acad Sci USA 1999;96:8573–8578.
28.
Azziz R, Saenger P: The second international symposium on the developmental aspects of androgen excess. Toronto, Canada, 20 June 2000. Trends in Endocrinol and Metab 2000;11:8:338–340.
29.
Pasquali R, Antenucci D, Casimirri F, et al: Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173–179.
30.
Kiddy DS, Hamilton-Fairley D, Seppälä M, et al: Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries; correlation with insulin and insulin-like growth factor-I. Clin Endocrinol 1989;31:757–763.
31.
Crave J, Fimbel S, Lejeune H, et al: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057–2062.
32.
Jakubowicz DJ, Nestler JE: 17α-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556–560.
33.
Nestler JE, Jakubowitcz D: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–4079.
34.
Nestler JE, Jakubowicz DJ, William SE, et al: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–1880.
35.
Dahlegren E, Janson PO, Johansson S, et al: Polycystic ovary syndrome and risk for myocardial infarction-evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992;71:599–604.
36.
Conway GS, Agrawal R, Betteridge DJ, Jacobs HS: Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119–125.
37.
Robinson S, Henderson AD, Gelding SV, et al: Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996;44:277–284.
38.
Franks S: Polycystic ovary syndrome: Approaching the millennium. Hum Reprod 1997;12(suppl):43–45.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.